Accordingly, we now believe that therapeutic targeting of MT1-MMP would be most beneficial for patients suffering from metastatic cancer and that our data would contribute to the design of the future anti-MT1-MMP clinical trials. Here, MMP14 is linked to metastatic malignant neoplasm.